|
18 Jun 2019 |
FDA approves Victoza® for the treatment of type 2 diabetes in children and adolescents aged 10-17 years
|
|
13 Jun 2019 |
First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology
|
|
13 Jun 2019 |
Noveome Biotherapeutics, Inc. Announces the First Patient Dosed in Phase 2 Open Label Clinical Trial Evaluating Topical Ocular Delivery of ST266 For the Treatment of Persistent Corneal Epithelial Defects
|
|
13 Jun 2019 |
Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)
|
|
12 Jun 2019 |
OrthoTrophix Presents Clinical Data at European Congress of Rheumatology
|
|
12 Jun 2019 |
Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial
|
|
10 Jun 2019 |
Avacta Group plc Hits Clinical Candidate Selection Milestone for Affimer PD-L1 Inhibitor
|
|
10 Jun 2019 |
Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog (insulin lispro), with superior post-meal blood glucose reductions
|
|
10 Jun 2019 |
Soliqua® Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments
|
|
09 Jun 2019 |
Lilly's tirzepatide demonstrates benefits in data presented at the American Diabetes Association's 79ᵗʰ Scientific Sessions
|
|
09 Jun 2019 |
Dance Biopharm Presents Encouraging Data from Phase 2 Clinical Trial of Dance 501 Inhaled Insulin Therapy at American Diabetes Association Meeting
|
|
09 Jun 2019 |
Oral semaglutide showed superior reductions in blood sugar vs Jardiance® and non-inferior blood sugar reductions vs Victoza® in adults with type 2 diabetes at 26 weeks
|
|
07 Jun 2019 |
La Jolla Pharmaceutical Company Announces Positive Results from Pre-Specified Interim Analysis of Phase 2 Study of LJPC-401 in Patients with Hereditary Hemochromatosis
|
|
07 Jun 2019 |
Lannett Announces Initiation Of Human Clinical Trial Of Biosimilar Insulin Glargine Versus Us Lantus
|
|
04 Jun 2019 |
Ra Pharmaceuticals Announces Expansion of Neuromuscular Portfolio with Clearance of IND Application for Zilucoplan for the Treatment of Immune-Mediated Necrotizing Myopathy
|
|
03 Jun 2019 |
Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency
|
|
02 Jun 2019 |
Ziopharm Oncology Provides Positive Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 ASCO Annual Meeting
|
|
02 Jun 2019 |
Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting
|
|
31 May 2019 |
Vigeo Therapeutics Presents Preliminary Results from Its Phase 1 Open Label Trial of VT1021 in Patients with Advanced Solid Tumors at ASCO
|
|
30 May 2019 |
Merz Pharma: Xeomin® (incobotulinumtoxinA) Receives European Approval for Treatment of Chronic Sialorrhea in Adults
|
|
29 May 2019 |
Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection
|
|
24 May 2019 |
Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication
|
|
23 May 2019 |
Pieris Pharmaceuticals and AstraZeneca Present Single- Ascending Dose Phase 1a Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the American Thoracic Society (ATS) 2019 International Conference
|
|
18 May 2019 |
U.S. FDA Approves GATTEX® (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)
|
|
14 May 2019 |
Zealand Pharma achieves primary and all key secondary endpoints in confirmatory Phase 3 trial with dasiglucagon for severe hypoglycemia
|
